Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

• Status: Not yet recruiting
• Trial end date: 2025-07-01

Summary

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

• Phase: Phase 1

Details

• Lead Sponsor: Taofeek Owonikoko
• Collaborator: AstraZeneca
• Treatments: Carboplatin; Durvalumab; Etoposide